Mass Tort & MDL Plaintiff Funding in Pennsylvania

Pennsylvania gives an injured plaintiff two years from the date of injury to bring a mass tort claim (42 Pa.C.S. §5524). Pennsylvania recognizes a discovery rule under its common law — most notably articulated in Fine v. Checcio, 582 Pa. 253 (2005) — that delays accrual until the plaintiff knows, or reasonably should know, of the injury and its cause, which is directly relevant to a latent-exposure mass tort claim. Pennsylvania does not have a general statute of repose for ordinary consumer products.

Pennsylvania applies modified comparative negligence with a 51% bar to negligence actions (42 Pa.C.S. §7102); how that bar interacts with a strict-liability mass tort claim specifically has been addressed by Pennsylvania courts with some nuance, consistent with the caution the same issue carries in the separate single-plaintiff product liability profile for this state, and should be confirmed against current Pennsylvania appellate authority for the specific mass tort theory being pursued.

Pennsylvania has no general statutory cap on compensatory damages in a mass tort action; the state constitution's remedies clause (Pa. Const. Art. III §18) has been a consistent barrier to caps of this kind outside narrow, specific statutory contexts.

Pennsylvania does not award traditional pre-judgment interest on unliquidated personal-injury damages, but Pa.R.C.P. 238 provides for 'delay damages' tied to litigation delay attributable to the defendant on an individual claim that proceeds to trial; a claim resolved through a global settlement matrix instead receives an allocated award under the settlement's own terms.

A Pennsylvania mass tort claim filed in or removable to federal court can be transferred to a federal MDL under 28 U.S.C. §1407 for coordinated pretrial proceedings. Pennsylvania is also home to one of the most prominent state-level mass tort venues in the country: the Complex Litigation Center of the Philadelphia County Court of Common Pleas administers a dedicated Mass Tort Program that has coordinated major pharmaceutical and consumer-product litigation, giving many Pennsylvania-filed mass tort plaintiffs a well-established state-court alternative or complement to a parallel federal MDL.

Pennsylvania has no dedicated consumer litigation funding statute. No statutory cap identified.

What is Philadelphia's Mass Tort Program and why does it matter for a Pennsylvania plaintiff?

The Complex Litigation Center of the Philadelphia County Court of Common Pleas runs a dedicated Mass Tort Program that has coordinated some of the country's largest pharmaceutical and consumer-product mass torts, giving Pennsylvania-filed claims a well-developed state-court venue with established case-management protocols, judges experienced in mass tort procedure, and — in many of these programs — a track record of global settlements.

For a Pennsylvania mass tort plaintiff, confirming whether the claim is proceeding through the Philadelphia Mass Tort Program, a federal MDL, or both in parallel is a useful early step, since the specific proceeding's history and pace — not the mass tort's national profile alone — drives the realistic timeline to a funding-relevant payout.

How does Pennsylvania's discovery rule affect a mass tort claim involving a long-latency injury?

Under Fine v. Checcio, the two-year clock doesn't start until the plaintiff knows, or reasonably should know, of both the injury and its cause, which for a slow-developing exposure-related condition can be well after the underlying exposure occurred.

As with the parallel discovery-rule doctrines in other states in this profile, the discovery date itself — not the date of exposure — is the fact that has to be established and documented for a Pennsylvania mass tort claim, since it determines whether the claim falls inside or outside the two-year filing window.